Volume 5, Supplement 3SupplementDocetaxel and Thalidomide as a Treatment Option for Androgen-Independent, Nonmetastatic Prostate CancerWilliam L DahutJames L GulleyPhilip M ArlenWilliam D FiggGregory D LeonardDocetaxelAndrogen-independent prostate cancerThalidomidePalliative
Volume 5, Supplement 3SupplementA New Formulation of Calcitriol (DN-101) for High-Dose Pulse Administration in Prostate Cancer TherapyTomasz M BeerWilliam David HennerHypercalcemiaCalcitriolAndrogen-independent prostate cancerHigh-dose
Volume 9, Supplement 2Review ArticlesTreatment Options for Hormone-Refractory Prostate CancerAndrogen-Independent Prostate CancerSam S ChangHormone-refractory prostate cancer is a disease that includes a variety of patients and represents a treatment dilemma for the practicing physician. Because of the diversity of this group, management strategies must be targeted to the clinical situations of the individual patients and their wishes. This article outlines a logical progression of treatment choices that currently exist in this rapidly evolving field, and the landmark chemotherapy trials involving docetaxel (SWOG 9916 and TAX 327) are reviewed. Although significant progress has been made in understanding and treating hormonerefractory prostate cancer, current treatments do not yet provide a cure, and important clinical trials continue to recruit patients. [Rev Urol. 2007;9(suppl 2):S13-S18]ChemotherapyHormone-refractory prostate cancerAndrogen-independent prostate cancerTaxanes
Volume 9, Supplement 2Review ArticlesNew Paradigms for Advanced Prostate CancerAndrogen-Independent Prostate CancerDaniel P PetrylakIn men with metastatic hormone-refractory prostate cancer, androgen blockade produces dramatic and rapid declines in prostate-specific antigen (PSA), bone pain, and urinary tract obstruction. Nevertheless, there have been limited options with at best palliative results for patients who progress despite a castrate testosterone level. This paradigm changed in 2004 with the publication of 2 randomized clinical trials that demonstrated a 20% to 24% survival benefit for docetaxel-based therapy when compared to mitoxantrone and prednisone, data that supported US Food and Drug Administration approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer. This article reviews the preliminary data and the timing and sequencing implications of ongoing clinical trials. Studies are evaluating the combination of docetaxel with agents that target bone, tumor vasculature, and the vitamin D receptor as well as second-line agents, such as satraplatin. The role of immune therapy is also evolving, and further studies will define the optimal timing of chemotherapy with immune therapy. [Rev Urol. 2007;9(suppl 2):S3-S12]Prostate cancerDocetaxelHormone-refractory prostate cancerAndrogen-independent prostate cancer